Cargando…
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
OBJECTIVES: It is controversial whether sodium glucose transporter (SGLT) 2 inhibitors increase glucagon secretion via direct inhibition of SGLT2 in pancreatic α cells. The role of SGLT1 in α cells is also unclear. We aimed to elucidate these points that are important not only for basic research but...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323192/ https://www.ncbi.nlm.nih.gov/pubmed/30416006 http://dx.doi.org/10.1016/j.molmet.2018.10.009 |
_version_ | 1783385712618373120 |
---|---|
author | Suga, Takayoshi Kikuchi, Osamu Kobayashi, Masaki Matsui, Sho Yokota-Hashimoto, Hiromi Wada, Eri Kohno, Daisuke Sasaki, Tsutomu Takeuchi, Kazusane Kakizaki, Satoru Yamada, Masanobu Kitamura, Tadahiro |
author_facet | Suga, Takayoshi Kikuchi, Osamu Kobayashi, Masaki Matsui, Sho Yokota-Hashimoto, Hiromi Wada, Eri Kohno, Daisuke Sasaki, Tsutomu Takeuchi, Kazusane Kakizaki, Satoru Yamada, Masanobu Kitamura, Tadahiro |
author_sort | Suga, Takayoshi |
collection | PubMed |
description | OBJECTIVES: It is controversial whether sodium glucose transporter (SGLT) 2 inhibitors increase glucagon secretion via direct inhibition of SGLT2 in pancreatic α cells. The role of SGLT1 in α cells is also unclear. We aimed to elucidate these points that are important not only for basic research but also for clinical insight. METHODS: Plasma glucagon levels were assessed in the high-fat, high-sucrose diet (HFHSD) fed C57BL/6J mice treated with dapagliflozin or canagliflozin. RT-PCR, RNA sequence, and immunohistochemistry were conducted to test the expression of SGLT1 and SGLT2 in α cells. We also used αTC1 cells and mouse islets to investigate the molecular mechanism by which SGLT1 modulates glucagon secretion. RESULTS: Dapagliflozin, but not canagliflozin, increased plasma glucagon levels in HFHSD fed mice. SGLT1 and glucose transporter 1 (GLUT1), but not SGLT2, were expressed in αTC1 cells, mouse islets and human islets. A glucose clamp study revealed that the plasma glucagon increase associated with dapagliflozin could be explained as a response to acute declines in blood glucose. Canagliflozin suppressed glucagon secretion by inhibiting SGLT1 in α cells; consequently, plasma glucagon did not increase with canagliflozin, even though blood glucose declined. SGLT1 effect on glucagon secretion depended on glucose transport, but not glucose metabolism. Islets from HFHSD and db/db mice displayed higher SGLT1 mRNA levels and lower GLUT1 mRNA levels than the islets from control mice. These expression levels were associated with higher glucagon secretion. Furthermore, SGLT1 inhibitor and siRNA against SGLT1 suppressed glucagon secretion in isolated islets. CONCLUSIONS: These data suggested that a novel mechanism regulated glucagon secretion through SGLT1 in α cells. This finding possibly explained the distinct effects of dapagliflozin and canagliflozin on plasma glucagon levels in mice. |
format | Online Article Text |
id | pubmed-6323192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-63231922019-01-18 SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels Suga, Takayoshi Kikuchi, Osamu Kobayashi, Masaki Matsui, Sho Yokota-Hashimoto, Hiromi Wada, Eri Kohno, Daisuke Sasaki, Tsutomu Takeuchi, Kazusane Kakizaki, Satoru Yamada, Masanobu Kitamura, Tadahiro Mol Metab Original Article OBJECTIVES: It is controversial whether sodium glucose transporter (SGLT) 2 inhibitors increase glucagon secretion via direct inhibition of SGLT2 in pancreatic α cells. The role of SGLT1 in α cells is also unclear. We aimed to elucidate these points that are important not only for basic research but also for clinical insight. METHODS: Plasma glucagon levels were assessed in the high-fat, high-sucrose diet (HFHSD) fed C57BL/6J mice treated with dapagliflozin or canagliflozin. RT-PCR, RNA sequence, and immunohistochemistry were conducted to test the expression of SGLT1 and SGLT2 in α cells. We also used αTC1 cells and mouse islets to investigate the molecular mechanism by which SGLT1 modulates glucagon secretion. RESULTS: Dapagliflozin, but not canagliflozin, increased plasma glucagon levels in HFHSD fed mice. SGLT1 and glucose transporter 1 (GLUT1), but not SGLT2, were expressed in αTC1 cells, mouse islets and human islets. A glucose clamp study revealed that the plasma glucagon increase associated with dapagliflozin could be explained as a response to acute declines in blood glucose. Canagliflozin suppressed glucagon secretion by inhibiting SGLT1 in α cells; consequently, plasma glucagon did not increase with canagliflozin, even though blood glucose declined. SGLT1 effect on glucagon secretion depended on glucose transport, but not glucose metabolism. Islets from HFHSD and db/db mice displayed higher SGLT1 mRNA levels and lower GLUT1 mRNA levels than the islets from control mice. These expression levels were associated with higher glucagon secretion. Furthermore, SGLT1 inhibitor and siRNA against SGLT1 suppressed glucagon secretion in isolated islets. CONCLUSIONS: These data suggested that a novel mechanism regulated glucagon secretion through SGLT1 in α cells. This finding possibly explained the distinct effects of dapagliflozin and canagliflozin on plasma glucagon levels in mice. Elsevier 2018-10-27 /pmc/articles/PMC6323192/ /pubmed/30416006 http://dx.doi.org/10.1016/j.molmet.2018.10.009 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Suga, Takayoshi Kikuchi, Osamu Kobayashi, Masaki Matsui, Sho Yokota-Hashimoto, Hiromi Wada, Eri Kohno, Daisuke Sasaki, Tsutomu Takeuchi, Kazusane Kakizaki, Satoru Yamada, Masanobu Kitamura, Tadahiro SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels |
title | SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels |
title_full | SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels |
title_fullStr | SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels |
title_full_unstemmed | SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels |
title_short | SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels |
title_sort | sglt1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of sglt2 inhibitors on plasma glucagon levels |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323192/ https://www.ncbi.nlm.nih.gov/pubmed/30416006 http://dx.doi.org/10.1016/j.molmet.2018.10.009 |
work_keys_str_mv | AT sugatakayoshi sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT kikuchiosamu sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT kobayashimasaki sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT matsuisho sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT yokotahashimotohiromi sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT wadaeri sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT kohnodaisuke sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT sasakitsutomu sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT takeuchikazusane sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT kakizakisatoru sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT yamadamasanobu sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels AT kitamuratadahiro sglt1inpancreaticacellsregulatesglucagonsecretioninmicepossiblyexplainingthedistincteffectsofsglt2inhibitorsonplasmaglucagonlevels |